These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1007 related items for PubMed ID: 19884549

  • 21. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
    Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F.
    J Clin Oncol; 2011 May 20; 29(15):2011-9. PubMed ID: 21502544
    [Abstract] [Full Text] [Related]

  • 22. Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.
    Garcia-Albeniz X, Pericay C, Alonso-Espinaco V, Alonso V, Escudero P, Fernández-Martos C, Gallego R, Gascón P, Castellví-Bel S, Maurel J.
    Tumour Biol; 2011 Apr 20; 32(2):417-24. PubMed ID: 21104178
    [Abstract] [Full Text] [Related]

  • 23. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K, Ciuleanu TE, Vrbanec D, Marton E, Messinger D, Liegl-Atzwanger B, Wrba F, Knittelfelder R, Lindner E, Zielinski CC, Streubel B, Brodowicz T.
    Clin Colorectal Cancer; 2015 Jun 20; 14(2):91-8. PubMed ID: 25666295
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials.
    Seligmann JF, Fisher D, Smith CG, Richman SD, Elliott F, Brown S, Adams R, Maughan T, Quirke P, Cheadle J, Seymour M, Middleton G.
    Ann Oncol; 2017 Mar 01; 28(3):562-568. PubMed ID: 27993800
    [Abstract] [Full Text] [Related]

  • 27. miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.
    Schou JV, Rossi S, Jensen BV, Nielsen DL, Pfeiffer P, Høgdall E, Yilmaz M, Tejpar S, Delorenzi M, Kruhøffer M, Johansen JS.
    PLoS One; 2014 Mar 01; 9(6):e99886. PubMed ID: 24940606
    [Abstract] [Full Text] [Related]

  • 28. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer.
    Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S.
    Clin Colorectal Cancer; 2014 Sep 01; 13(3):164-71. PubMed ID: 25069797
    [Abstract] [Full Text] [Related]

  • 29. The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.
    Sohn BS, Kim TW, Lee JL, Ryu MH, Chang HM, Kang YK, Park HS, Na YS, Jang SJ, Kim JC, Lee JS.
    Oncology; 2009 Sep 01; 77(3-4):224-30. PubMed ID: 19738388
    [Abstract] [Full Text] [Related]

  • 30. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.
    Acta Oncol; 2014 Jul 01; 53(7):852-64. PubMed ID: 24666267
    [Abstract] [Full Text] [Related]

  • 31. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
    Ye JX, Liu Y, Qin Y, Zhong HH, Yi WN, Shi XY.
    World J Gastroenterol; 2015 Feb 07; 21(5):1595-605. PubMed ID: 25663779
    [Abstract] [Full Text] [Related]

  • 32. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
    Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, d'Ario G, Cisar L, Labianca R, Cunningham D, Nordlinger B, Bosman F, Van Cutsem E.
    J Natl Cancer Inst; 2012 Nov 07; 104(21):1635-46. PubMed ID: 23104212
    [Abstract] [Full Text] [Related]

  • 33. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
    Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson AB, Mowat RB, Spiegelman D, Goldberg RM, Bertagnolli MM, Meyerhardt JA, Fuchs CS, Alliance for Clinical Trials in Oncology.
    J Natl Cancer Inst; 2013 Dec 04; 105(23):1789-98. PubMed ID: 24231454
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
    García-Foncillas J, Díaz-Rubio E.
    Clin Transl Oncol; 2010 Aug 04; 12(8):533-42. PubMed ID: 20709651
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
    Stintzing S, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, Jäger E, Heintges T, Stoll C, Giessen C, Modest DP, Neumann J, Jung A, Kirchner T, Scheithauer W, Heinemann V.
    Ann Oncol; 2012 Jul 04; 23(7):1693-9. PubMed ID: 22219013
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials.
    Lv ZC, Ning JY, Chen HB.
    Tumour Biol; 2014 Dec 04; 35(12):11741-50. PubMed ID: 25417200
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 51.